Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

ng to support the manufacture of MOXATAG, and for working capital and general corporate purposes. In addition, the financing is designed to provide the Company with additional financial flexibility in its ongoing strategic discussions.

Process to Explore Strategic Alternatives Ongoing

In February 2008, MiddleBrook announced that it engaged Morgan Stanley as its strategic advisor in the Company's ongoing strategic evaluation process. MiddleBrook is evaluating a full range of available strategic alternatives intended to further enhance shareholder value.

Strategic alternatives the Company may pursue could include, but are not limited to, continued execution of the Company's operating plan, the sale of some or all of the Company's assets, partnering or other collaboration agreements, or a merger or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not intend to disclose developments with respect to this process unless and until the evaluation of strategic alternatives has been completed.

FINANCIAL DETAILS

-- Total revenue, resulting entirely from net Keflex product sales, was

$2.9 million in the fourth quarter of 2007, compared to revenue of $3.1

million in the prior quarter, and $1.2 million for the fourth quarter

of 2006. Revenue during the full year of 2007 was $10.5 million, up

from revenue of $4.8 million during the full year of 2006. Increased

product sales in 2007 were mainly attributable to the Company's Keflex

750 mg strength capsules which were launched during the second half of

2006.

-- Operating expenses. Research and development expenses, which primarily

consist of salaries, stock-based compensation, and related expenses for

<
'/>"/>
SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... DALLAS , July 29, 2014 ... Market Slide Scanners (Whole Slide Imaging), Analytics (Image Analysis Software), ... Storage - Global Forecasts & Trends to 2018", published ... and restraints in geographies such as North ... Asia , and the Rest of the ...
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. announced today ... Inc., to provide access to Nanosyn,s microfluidics screening ... platform for novel small molecule therapeutics. ... to work with FORMA Therapeutics to explore key ... homeostasis. FORMA Therapeutics, decision to work with us ...
(Date:7/29/2014)... 2014  Cannabis Science, Inc. (OTC: CBIS), a ... and related consulting, applauds the Editorial Board of ... position in opposition to current federal law on ... The New York Times also announces a series ... the issue called "High Time:  An Editorial Series ...
(Date:7/29/2014)... Denver, CO (PRWEB) July 29, 2014 ... and soiled linen collection and transport solutions for hospitals, ... Society for Healthcare Engineering (ASHE) Annual Conference & Technical ... TransVac will present its technology for making hospitals cleaner, ... operational costs over the hospital’s life cycle. Staff ...
Breaking Biology Technology:Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2
... , PHILADELPHIA, July 13 ERT (Nasdaq: ... technology, and other services to the biopharmaceutical, medical device, and related ... 2009 second quarter on Thursday, July 30, 2009 after the market ... at 5:00 PM EDT that day. , , ...
... , SAN JOSE, Calif., July ... of measurement and control solutions for biologics applications today announced ... BIIB ) aimed at evaluating emerging technologies for single-use bioprocessing. ... control algorithms. , , ...
... LEXINGTON, Mass. and HEIDELBERG, Germany, July 13 ... first human cancer biochip for HybSelect, febit,s highly automated technology for ... biochip features 115 important genes which are reported to be associated ... , , "Molecular signatures defined ...
Cached Biology Technology:ERT to Announce 2009 Second Quarter Results on July 30, 2009 2Finesse Solutions Forges Agreement With Leading Biotechnology Company for Single-Use Technology Exploration 2First Catalog Cancer Biochip for Sequence Capture Now Available from febit 2
(Date:7/28/2014)... additional coral communities showing signs of damage from the Deepwater ... spill in the Gulf of Mexico. The discovery was made ... at Penn State University. A paper describing this work and ... of Mexico will be published during the last week of ... Proceedings of the National Academy of Sciences . , ...
(Date:7/28/2014)... -- Fifteen years ago, MIT professor John Essigmann and colleagues ... an HIV drug. They thought if they could induce the ... and eventually die out a strategy that our immune ... such a drug, which caused HIV to mutate at an ... virus from patients in a small clinical trial reported in ...
(Date:7/28/2014)... other forms of dementia, but the research community is ... Washington bioengineers have a designed a peptide structure that ... proteins into a state that,s linked to widespread diseases ... and Lou Gehrig,s disease. The synthetic molecule blocks these ... an abnormally folded form by targeting a toxic intermediate ...
Breaking Biology News(10 mins):Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... Institute Associate Professor Marisa Roberto has been awarded the ... the Ordine al Merito della Repubblica Italiana (Order of ... addictive behavior. Traditionally bestowed by the president ... "merit acquired by the nation" in literature, the arts, ...
... been told you,re going on a trip. The only problem ... traveling, or what you,ll do when you get there. ... is on right now. As land use, human population, consumption ... with complex and unpredictable interactions, it,s anybody,s guess where we,ll ...
... recent book chapter about sugar-based chemicals is topping ... list. "Sugar-Based Chemicals for Environmentally Sustainable Applications" ... http://pubs.acs.org/doi/abs/10.1021/bk-2010-1061.ch001 and is racking up kudos. ... and research professors A. J. East and W. ...
Cached Biology News:U of M researchers find smart decisions for changing environmental times 2Sugar-based chemicals book chapter by NJIT professor takes ACS kudos 2
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Each 72-well MiniTray is low profile, with lid. Conical well shape, 10 l....
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
...
Biology Products: